CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
商业化 CAR-T 细胞治疗后的第二原发恶性肿瘤：FDA 不良事件报告系统分析
英文原题：Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.
查看英文原题
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在食品药品监督管理局不良事件报告系统中，12 394份CAR-T 细胞疗法后的不良事件报告中，有536份（4.3%）报告了第二原发恶性肿瘤。髓系和T细胞肿瘤的报告频率不成比例地更高，值得进一步随访。
展开英文摘要原文
Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.
论文信息
- 作者
- Elsallab M、Ellithi M、Lunning MA、D'Angelo C、Ma J、Perales MA、Frigault M、Maus MV
- 第一作者单位
- Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA.United States
- 通讯作者单位
- Cellular Immunotherapy Program, Mass General Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA.United States
- 文献类型
- 读者来信
- 期刊
- Blood2024 May 16
- 原文标识
- PubMed 38483155 · DOI 10.1182/blood.2024024166